A randomized, double-blind, placebo managed, section III medical demo evaluated the efficacy and safety profile of adalimumab as being a monotherapy in sufferers with RA who had failed to answer csDMARDs [191]. The final results confirmed equally statistically important enhancement inside the condition action and a very good safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/